Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

US Patent 11285159 · Granted Mar 29, 2022

Estimated economic value: $1,437,509,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods for treating HCV2022
Method for treating HCV2019
Methods for treating HCV2016
Methods for treating HCV2015
Methods for treating HCV2015
Methods for treating HCV2014
Methods for treating HCV2014
Methods for treating HCV2014
Methods for treating HCV2014
Methods for treating HCV2013
Methods for treating HCV2013